Barry Greene: Yes. Let me start with the second part of that I’ll talk about first, so we believe the unmet need in MDD and PPD is so great. As we talked about 6 million to 7 million dynamic patients with — looking for new treatment options in MDD, 0.5 million moms that should be diagnosed with pressure in the year. That patient population is so significant, unmet need, so significant. That will remain our focus for the foreseeable future. If we can win in depression, we can really help millions of patients. So we’ll provide sort of future indications at later points in time. But right now, the focus is absolutely win in depression, trying to help as many people as we can. In terms of how at launch the drug will be used, as Chris already highlighted in PPD, we’d like to have Zuranolone being standard-of-care.
The only oral if approved, the only oral treatment approved specifically to treat PPD. And in MDD, our target is to educate physicians that Zuranolone should be used as your first switch or first add on should the patient not be adequately controlled with whatever they’re taking and that is our first .
Chris Benecchi: Yes. I think what I’d add to that, Barry, is if left to things to just happen, I could see where physicians across all different areas of treatment, use new products later. But here, what we have through not only the positioning and the identification of appropriate places of use, despite the idea of proactive value-based agreements. Proactive value-based agreements are designed to really ensure that physicians have access earlier in the treatment paradigm. So that you don’t have the owner’s prior authorization in step edits, which can ultimately take a new medication and push it to later utilization. So it’s — so important that we work across all stakeholders to make sure that physicians have the ability to really access really the treatment process and use it where they want to launch.
Operator: We’ll hear next from Joon Lee from Truist Securities.
Joon Lee: Hi thanks for taking our questions. Looking forward to additional data from get package? And also quickly, you mentioned lifecycle management for Zuranolone. Can you share what you have in mind? Thank you.
Barry Greene: Yes, Joon. Thanks for the question. So we’re not coming more on lifecycle management. As we commented earlier on the call, we’ll have a regular series of updates with the .
Operator: Thank you, everyone. That will conclude the Q&A portion of today’s call. With that, I will turn it back over to Mr. Barry for closing remarks.
Barry Greene: Thanks, Lynette, and thanks again to everyone for joining us this morning to review our fourth quarter and full-year 2022 results. Our progress in the fourth quarter and throughout 2022 is the direct result of teamwork and dedication from everyone in our and our partner’s organization, so I want to thank everybody. As we make critical advancements, progressive development activities across brain health, we maintain a position of strength as we advance our mission to develop and launch transformative medicines for patients in need. Thanks again everyone and have a wonderful
